Mitozantrone  -  Cytotoxic  Antibiotic

  

 Action :

It is an anthracenedione antitumour agent which is a potent inhibitor of RNA & DNA synthesis. It may react with cell membranes & alter the functions of these membranes. It can also react with cytochrome P-450 reductase in the presence of NADPH to generate toxic free radicals.

  

 Indication :

Chronic Myelogenous leukaemia, non Hogdgkin's lymphoma, carcinoma of breast, adult acute nonlymphocytic leukaemia (ANLL).

    

 Contraindication :

Severe Myelosuppression, abnormal cardiac function from prior anthracycline exposure. Severe hepatic impairment.

  

 Adverse-Effects :

Nausea, vomiting, bluegreen sclera, stomatitis, bone marrow depression, alopecia, hepatic damage, renal failure, cardiotoxicity. Dyspnoea, rash.

  

 Special Precaution :

Preexisting cardiac disease, prior radiotherapy. Monitor blood count, cardiac function and uric acid levels. Hepatic impairment.

    

 Dosage :

Adults

:

Brest cancer & lymphoma : Initially 14mg / m2 BSA as single IV dose; repeat at 21 day intervals.

ANLL : 12mg / m2 daily for 5 days.

Note

:

Mitozantrone solution must be diluted prior to use with either normal saline or 5% dextrose.

  

 Strength & Packing :

2mg / ml,  10ml  Injection.

  
*  for the use of a registered Medical practitioner or a Hospital or a Laboratory only.

  

  

Export Product List


[Go Back to the Export product list]

   
  

   

  

  

Disclaimer : This guide is provided for information purposes only, and for use of a registered medical practitioner or a hospital or a laboratory only. The authors, webmaster, or respective references / links are no way responsible for the content of the information. Although a concerted effort has been made to ensure the validity of the information contained in this document, we give no assurance for the accuracy of the information in this documents.